Tracked deals
7
7 tracked deals across 2019-2024.
Private Equity Firm
Financial Services
Charme Capital Partners
Milan, Lombardy, Italy
European mid-market private equity fund manager supporting management teams and shareholders to achieve transformational change, growth and internationalisation. Offices in Milan, London and Madrid; invests across Europe in businesses with an enterprise value typically in the €100m to €500m range, including healthcare and med-tech themes.
- Focus Areas
- Private equity fund management, Mid-market buyouts, Healthcare and med-tech investments
- Website
- charmecapitalpartners.com
Recent pace
0
0 tracked deals announced in the last 12 months.
Deal mix
Buyout
7 buyout
Charme Capital Partners Acquisition Volume by Year
Last 5 years
Supporting Data
Recent Transactions
-
- Buyer
- Charme Capital Partners SGR (Charme IV fund)
- Target
- Animalia
- Industry
- Veterinary
- Location
- Lombardy, Italy
- Type
- Buyout
Charme Capital Partners (via its Charme IV fund) has agreed to take a 56% stake in Animalia through a capital increase, partnering with founders Antonino Santalucia and Giorgio Romani who will remain co-CEOs and minority shareholders. The investment will fund Animalia's consolidation and organic growth plan—including targeted add‑ons and expansion of clinic services—across its network of more than 75 clinics in Italy.
-
June 22, 2023
- Buyer
- Charme Capital Partners (Charme IV)
- Target
- Bright Futures Care
- Seller
- Livingbridge
- Industry
- Healthcare Services
- Location
- England, United Kingdom
- Type
- Buyout
Charme Capital Partners (Charme IV) has acquired Bright Futures Care, a specialist provider of education and residential care for people with autism and learning disabilities across the North-West of England. Livingbridge has retained a minority stake; terms were not disclosed and Charme said the investment will support further organic growth and geographic expansion across the UK.
-
October 27, 2022
- Buyer
- Charme Capital Partners SGR S.p.A. (Charme IV fund)
- Target
- Tema Sinergie S.p.A.
- Seller
- Founders and current shareholders of Tema Sinergie (including Luciano Piancastelli, Amedeo Laghi, Aurelio Romualdi and Andrea Peroni)
- Industry
- Medical Devices
- Location
- Emilia-Romagna, Italy
- Type
- Buyout
Charme Capital Partners (through its Charme IV fund) will acquire a majority stake in Tema Sinergie S.p.A., an Italian manufacturer of isolators and filling/inspection systems for nuclear medicine and biotech pharmaceutical production. The investment will support Tema Sinergie's international expansion, product innovation and growth in theragnostic and biotech segments while preserving management continuity under CEO Stefano Piancastelli.
-
March 1, 2022
- Buyer
- Charme Capital Partners
- Target
- Prism Healthcare
- Seller
- Limerston Capital, Management team
- Industry
- Medical Devices
- Location
- West Yorkshire, United Kingdom
- Type
- Buyout
Charme Capital Partners’ Charme IV fund has acquired Prism Healthcare, a UK-based manufacturer and provider of specialist patient handling and care equipment. Limerston Capital will remain invested alongside the management team; Charme’s investment will support Prism’s organic growth, international expansion and continued buy-and-build strategy.
-
February 28, 2022
- Buyer
- Charme Capital Partners, Miura Capital
- Target
- INDIBA
- Seller
- Magnum Capital
- Industry
- Medical Devices
- Location
- Catalonia, Spain
- Type
- Buyout
Private equity firms Charme Capital Partners and Miura Capital have completed the acquisition of INDIBA, a Barcelona-based developer of 448 kHz radio-frequency medical devices for physiotherapy, aesthetics and veterinary markets, from Magnum. The deal positions INDIBA for a next phase of growth, with plans to expand market reach, product portfolio and operations under the new ownership.
-
- Buyer
- Charme Capital Partners SGR S.p.A. (Charme IV fund)
- Target
- Bianalisi
- Seller
- Bianalisi's existing shareholders (including founder Giuliano Caslini)
- Industry
- Healthcare Services
- Location
- Lombardy, Italy
- Type
- Buyout
Charme Capital Partners (via its Charme IV fund) has agreed to acquire a majority stake in Italian diagnostics and outpatient services group Bianalisi. The investment will support Bianalisi's consolidation push across Italy, expansion of service capabilities (including preventive genetics and telemedicine) and continued partnership with founder Giuliano Caslini, who will remain Chairman and CEO.
-
- Buyer
- EQT (EQT VIII), Charme Capital Partners, Igenomix management
- Target
- Igenomix
- Seller
- Charme Capital Partners, Igenomix management, Other minority owners
- Industry
- Biotechnology
- Location
- Valencian Community, Spain
- Type
- Buyout
EQT VIII (EQT Partners) has agreed to acquire a majority stake in Igenomix, a Valencia-headquartered leader in reproductive genetic services, from Charme Capital, management and other minority owners. Charme Capital and the Igenomix management team will reinvest significant minority stakes, and EQT will support the company's continued international expansion and R&D-led growth.
Related Acquisition Pages
Medical Devices Buyers & Acquisitions
3 tracked deals by Charme Capital Partners.
Healthcare Services Buyers & Acquisitions
2 tracked deals by Charme Capital Partners.
Biotechnology Buyers & Acquisitions
1 tracked deal by Charme Capital Partners.
Veterinary Buyers & Acquisitions
1 tracked deal by Charme Capital Partners.
Selling a company? Get in front of buyers like Charme Capital Partners
Turn tracked acquisition activity into an outreach-ready buyer list.